Published in Cell Mol Neurobiol on June 29, 2006
Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy. Nat Genet (2009) 3.83
Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children. Clin Pharmacol Ther (2013) 2.70
Vascular actions of estrogens: functional implications. Pharmacol Rev (2008) 2.52
The COMT Val108/158Met polymorphism and medial temporal lobe volumetry in patients with schizophrenia and healthy adults. Neuroimage (2009) 1.05
Pain modality- and sex-specific effects of COMT genetic functional variants. Pain (2013) 1.02
Effects of age, genes, and pulse pressure on executive functions in healthy adults. Neurobiol Aging (2009) 0.98
Platinum-induced neurotoxicity and preventive strategies: past, present, and future. Oncologist (2015) 0.93
Proteomic changes in rat hippocampus and adrenals following short-term sleep deprivation. Proteome Sci (2008) 0.87
Human S-adenosylhomocysteine hydrolase: common gene sequence variation and functional genomic characterization. J Neurochem (2009) 0.82
Chemotherapy refractory testicular germ cell tumor is associated with a variant in Armadillo Repeat gene deleted in Velco-Cardio-Facial syndrome (ARVCF). Front Endocrinol (Lausanne) (2012) 0.81
Xenobiotic-sensing nuclear receptors involved in drug metabolism: a structural perspective. Drug Metab Rev (2012) 0.81
Catechol O-methyltransferase pharmacogenomics and selective serotonin reuptake inhibitor response. Pharmacogenomics J (2010) 0.79
The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease. PLoS One (2016) 0.79
Identification, characterization, and ontogenic study of a catechol O-methyltransferase from zebrafish. Aquat Toxicol (2010) 0.76
Reduced 3-O-methyl-dopa levels in OCD patients and their unaffected parents is associated with the low activity M158 COMT allele. Am J Med Genet B Neuropsychiatr Genet (2010) 0.76
Aggresomes: a cellular response to misfolded proteins. J Cell Biol (1998) 11.24
Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci U S A (2001) 9.42
Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol (2000) 9.40
The deacetylase HDAC6 regulates aggresome formation and cell viability in response to misfolded protein stress. Cell (2003) 7.71
Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics (1996) 6.83
Inheritance and drug response. N Engl J Med (2003) 5.78
Posttranslational quality control: folding, refolding, and degrading proteins. Science (1999) 5.55
COMT val158met genotype affects mu-opioid neurotransmitter responses to a pain stressor. Science (2003) 4.72
Enzymatic O-methylation of epinephrine and other catechols. J Biol Chem (1958) 4.16
Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet (1980) 3.71
Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med (2002) 3.53
Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci U S A (1997) 3.53
Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemia. Lancet (1990) 3.38
Hassles with taking out the garbage: aggravating aggresomes. Traffic (2002) 3.27
S-Adenosylmethionine; a new intermediate formed enzymatically from L-methionine and adenosinetriphosphate. J Biol Chem (1953) 3.16
Molecular mechanisms of estrogen carcinogenesis. Annu Rev Pharmacol Toxicol (1996) 2.91
Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient. Lancet (1993) 2.66
From the cradle to the grave: molecular chaperones that may choose between folding and degradation. EMBO Rep (2001) 2.55
The clinical pharmacology of 6-mercaptopurine. Eur J Clin Pharmacol (1992) 2.53
The distribution and properties of a histamine-methylating enzyme. J Biol Chem (1959) 2.52
Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther (1989) 2.51
Purification and properties of phenylethanolamine-N-methyl transferase. J Biol Chem (1962) 2.49
Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J Pediatr (1991) 2.24
Cytoplasmic dynein/dynactin mediates the assembly of aggresomes. Cell Motil Cytoskeleton (2002) 2.11
Inheritance of low erythrocyte catechol-o-methyltransferase activity in man. Am J Hum Genet (1977) 1.94
An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res (1997) 1.92
Human erythrocyte thiopurine methyltransferase: radiochemical microassay and biochemical properties. Clin Chim Acta (1978) 1.81
Genetic polymorphisms in catechol-O-methyltransferase, menopausal status, and breast cancer risk. Cancer Res (1998) 1.80
Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev (1975) 1.79
The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics (1999) 1.76
Human arsenic methyltransferase (AS3MT) pharmacogenetics: gene resequencing and functional genomics studies. J Biol Chem (2006) 1.74
Human liver nicotinamide N-methyltransferase. cDNA cloning, expression, and biochemical characterization. J Biol Chem (1994) 1.69
Pharmacogenomics: bench to bedside. Nat Rev Drug Discov (2004) 1.63
Thiopurine S-methyltransferase pharmacogenetics: insights, challenges and future directions. Oncogene (2006) 1.62
Genomic organization of the human catechol O-methyltransferase gene and its expression from two distinct promoters. Eur J Biochem (1994) 1.62
Thiopurine pharmacogenetics in leukemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentrations. Clin Pharmacol Ther (1987) 1.62
Catechol-O-methyltransferase: thermolabile enzyme in erythrocytes of subjects homozygous for allele for low activity. Science (1979) 1.62
Human liver catechol-O-methyltransferase pharmacogenetics. Clin Pharmacol Ther (1990) 1.60
Thiopurine methyltransferase pharmacogenetics: human gene cloning and characterization of a common polymorphism. DNA Cell Biol (1996) 1.53
Human catechol O-methyltransferase genetic variation: gene resequencing and functional characterization of variant allozymes. Mol Psychiatry (2004) 1.53
Serum dopamine-beta-hydroxylase activity. Circ Res (1971) 1.52
Histamine N-methyltransferase pharmacogenetics: association of a common functional polymorphism with asthma. Pharmacogenetics (2000) 1.51
Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia (2000) 1.48
Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res (1999) 1.47
Thiopurine pharmacogenetics: clinical and molecular studies of thiopurine methyltransferase. Drug Metab Dispos (2001) 1.45
Inheritance of very low serum dopamine-beta-hydroxylase activity. Am J Hum Genet (1975) 1.40
A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci U S A (1995) 1.36
Serum dopamine beta-hydroxylase. Pharmacol Rev (1978) 1.31
Correlation of erythrocyte catechol-O-methyltransferase activity between siblings. Nature (1974) 1.28
Methyltransferase enzymes in red blood cells. J Pharmacol Exp Ther (1971) 1.28
Human liver thiopurine methyltransferase pharmacogenetics: biochemical properties, liver-erythrocyte correlation and presence of isozymes. Pharmacogenetics (1992) 1.26
Human histamine N-methyltransferase pharmacogenetics: common genetic polymorphisms that alter activity. Mol Pharmacol (1998) 1.25
Metabolism of thiopyrimidines and thiopurines. S-Methylation with S-adenosylmethionine transmethylase and catabolism in mammalian tissues. J Biol Chem (1963) 1.25
Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics. Pharmacogenet Genomics (2005) 1.23
Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation. Proc Natl Acad Sci U S A (2005) 1.20
Thiopurine S-methyltransferase pharmacogenetics: chaperone protein association and allozyme degradation. Pharmacogenetics (2003) 1.12
Thiopurine methyltransferase biochemical genetics: human lymphocyte activity. Biochem Genet (1982) 1.12
Enhanced proteasomal degradation of mutant human thiopurine S-methyltransferase (TPMT) in mammalian cells: mechanism for TPMT protein deficiency inherited by TPMT*2, TPMT*3A, TPMT*3B or TPMT*3C. Pharmacogenetics (1999) 1.11
Genetics of red cell COMT activity: analysis of thermal stability and family data. Am J Med Genet (1981) 1.09
Human kidney thiopurine methyltransferase. Purification and biochemical properties. Biochem Pharmacol (1983) 1.07
Catechol-O-methyltransferase activity: a determinant of levodopa response. Clin Pharmacol Ther (1980) 1.07
Microassay of human erythrocyte catechol-O-methyltransferase: removal of inhibitory calcium ion with chelating resin. Clin Chim Acta (1975) 1.06
Membrane-bound catechol-O-methyltransferase: a reevaluation of its role in the O-methylation of the catecholamine neurotransmitters. Rev Physiol Biochem Pharmacol (1992) 1.04
Human thiopurine methyltransferase: molecular cloning and expression of T84 colon carcinoma cell cDNA. Mol Pharmacol (1993) 1.02
Pharmacogenetics: inherited variation in amino acid sequence and altered protein quantity. Clin Pharmacol Ther (2004) 1.01
Thiopurine methyltransferase. Aromatic thiol substrates and inhibition by benzoic acid derivatives. Mol Pharmacol (1983) 1.00
Human phenylethanolamine N-methyltransferase pharmacogenomics: gene re-sequencing and functional genomics. J Neurochem (2005) 0.98
Human liver xanthine oxidase: nature and extent of individual variation. Clin Pharmacol Ther (1991) 0.94
Thiopurine methyltransferase polymorphic tandem repeat: genotype-phenotype correlation analysis. Clin Pharmacol Ther (2000) 0.93
Identification of two novel sequence variants affecting thiopurine methyltransferase enzyme activity. Pharmacogenetics (2004) 0.92
Catechol-o-methyltransferase biochemical genetics: human lymphocyte enzyme. Biochem Genet (1981) 0.91
Human thiopurine methyltransferase pharmacogenetics. Kindred with a terminal exon splice junction mutation that results in loss of activity. J Clin Invest (1998) 0.91
Human nicotinamide N-methyltransferase gene: molecular cloning, structural characterization and chromosomal localization. Genomics (1995) 0.90
Thiol methylation pharmacogenetics: heritability of human erythrocyte thiol methyltransferase activity. Clin Pharmacol Ther (1983) 0.89
Human nicotinamide N-methyltransferase pharmacogenetics: gene sequence analysis and promoter characterization. Pharmacogenetics (1999) 0.87
Erythrocyte catechol-O-methyltransferase activity in a Swedish population. Clin Genet (1981) 0.86
Human indolethylamine N-methyltransferase: cDNA cloning and expression, gene cloning, and chromosomal localization. Genomics (1999) 0.85
Human histamine N-methyltransferase pharmacogenetics: cloning and expression of kidney cDNA. Mol Pharmacol (1994) 0.84
The enzymatic N-methylation of serotonin and other amines. J Pharmacol Exp Ther (1962) 0.83
Human histamine N-methyltransferase gene: structural characterization and chromosomal location. Biochem Biophys Res Commun (1996) 0.82
Platelet phenol sulfotransferase and erythrocyte catechol-O-methyltransferase activities: correlation with methyldopa metabolism. Clin Pharmacol Ther (1984) 0.82
Phenol-O-methyltransferase. Biochim Biophys Acta (1968) 0.82
Presence of two distinct catechol -O- methyltransferase activities in red blood cells. Biochimie (1971) 0.81
Characterization of a variable number tandem repeat region in the thiopurine S-methyltransferase gene promoter. Pharmacogenetics (1999) 0.81
Correlation of low and high affinity thiol methyltransferase and phenol methyltransferase activities in human erythrocyte membranes. Clin Chim Acta (1983) 0.79